ACTRN12615000915550尚未招募2 期
Peg-interferon-alfa to achieve HBsAg loss in chronic hepatitis Bunder long-term viral suppression with nucleoside analogues
Peter Angus0 个研究点目标入组 50 人开始时间: 2015年9月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •*Informed consent
- •*Age > 18 years
- •*HBsAg-positive
- •*HBeAg negative
- •*On entecavir or tenofovir > 18 months
- •*HBV DNA level undetectable for > 18 months
- •*HBsAg < 1000 IU/mL
排除标准
- •Severe liver disease which excludes them from peg-interferon
研究者
相似试验
尚未招募
2 期
A study of peginterferon-alfa intervention to achieve hepatitis B surface antigen loss in multi-drug resistant chronic hepatitis B participants under long-term viral suppression with tenofovir DF +/- lamivudine salvage therapy (TDF-109 cohort)ACTRN12613000946718Peter Angus55
Unknown
3 期
A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis BChronic Hepatitis BAgHbs NegativationNCT01172392ANRS, Emerging Infectious Diseases185
已完成
4 期
Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral TreatmentChronic Hepatitis BNCT00226382Chinese University of Hong Kong50
Unknown
4 期
The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAgChronic Hepatitis BNCT02745704Third Affiliated Hospital, Sun Yat-Sen University200
Unknown
4 期
The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAgChronic Hepatitis BNCT02838810Third Affiliated Hospital, Sun Yat-Sen University200